ConcertAI's TeraRecon has added Bot Image's prostate cancer detection and diagnosis artificial intelligence (AI) software to its Eureka Clinical AI platform.
Bot Image secured clearance for the prostate cancer software, ProstatID, from the U.S. Food and Drug Administration (FDA) in July of last year for use with biparametric MRI. The software has been shown to help increase the detection of the disease while also decreasing false positives, TeraRecon said.
